Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CyBio AG Delivers Major Contract to Boehringer Ingelheim

Published: Saturday, February 08, 2014
Last Updated: Saturday, February 08, 2014
Bookmark and Share
Company delivers a robotics system to Boehringer Ingelheim for replicating plates.

CyBio AG has delivered a robotics system to Boehringer Ingelheim for replicating plates for its compound management activities in its Biberach location as part of a major contract.

For the company, a subsidiary of Analytik Jena, the contract comprised delivery of the complete solution including plate storage, the robot system, pipettors and the system controls. The order value lies in the upper six-figure range.

"We are happy about this major contract, as Boehringer Ingelheim has been a valued customer for more than a decade and has placed their trust in us once again for this far-reaching project," says CyBio Executive Board member Thomas Moore. "We have replaced a unit that has been in use for about ten years with the new system and, in addition our expertise in project business, have added core CyBio products to the system."

The system, which is now in operation, includes the pipettor workstation CyBi®-Well vario with 384 pipetting heads and accessories, the CyBi®-Drop3D for dispensing as well as numerous CyBi®-QuadStack microplate storage units.

"In the end, Boehringer Ingelheim chose us based on a notable reference from a large crop science company for whom we successfully implemented a project of a similar size in the past year," Moore continued.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CyBio to be Merged into Analytik Jena
Analytik Jena AG is planning to merge the business of its subsidiary CyBio AG with its core business in the Life Science business unit.
Friday, April 11, 2014
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!